These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Agranulocytosis during use of aprindine]. van Leeuwen R Ned Tijdschr Geneeskd; 1976 Sep; 120(36):1549-50. PubMed ID: 967294 [No Abstract] [Full Text] [Related]
8. [Agranulocytosis caused by aprindine. Apropos of a new case]. González Juanatey JR; Amaro Cendon A; Pose Reino A; Torre Carballada A; Rubio Alvarez J; Gil de la Peña M Med Clin (Barc); 1984 May; 82(19):865-6. PubMed ID: 6738221 [No Abstract] [Full Text] [Related]
9. [Agranulocytosis after use of aprindine (Fiboran)]. Poortermans JC; Majid PA; Roos JP Ned Tijdschr Geneeskd; 1976 Nov; 120(46):2011-2. PubMed ID: 1012364 [No Abstract] [Full Text] [Related]
10. [Agranulocytosis and aprindine]. Rouveix B; Lassoued K; Abel L; Regnier B Therapie; 1986; 41(6):517-8. PubMed ID: 3810547 [No Abstract] [Full Text] [Related]
14. [Fatal course of agranulocytosis during antiarryhthmic aprindine therapy]. Hausamen TU; Weber FW Dtsch Med Wochenschr; 1977 Oct; 102(42):1523-4. PubMed ID: 913289 [No Abstract] [Full Text] [Related]
15. Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: The International Agranulocytosis and Aplastic Anemia Study. Kelly JP; Kaufman DW; Shapiro S Clin Pharmacol Ther; 1991 Mar; 49(3):330-41. PubMed ID: 1672513 [TBL] [Abstract][Full Text] [Related]